Begoña Quintana-Villamandos

Dr. Begoña Quintana-Villamandos


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
AAAna Arnalich-Montiel
Ana Arnalich-Montiel
ABAlba Burgos
Alba Burgos
LPLaia Pazó-Sayós
Laia Pazó-Sayós
BQBegoña Quintana-Villamandos
Begoña Quintana-Villamandos
Acute ischemic stroke (AIS) is a challenging disease, which needs urgent comprehensive management. Endovascular thrombectomy (EVT), alone or combined with iv thrombolysis, is currently the most effective therapy for patients with acute ischemic stroke (AIS). However, only a limited number of patients are eligible for this time-sensitive treatment. Even though there is still significant room for improvement in the management of this group of patients, up until now there have been no alternative therapies approved for use in clinical practice. However, there is still hope, as clinical research with novel emerging therapies is now generating promising results. These drugs happen to stop or palliate some of the underlying molecular mechanisms involved in cerebral ischemia and secondary brain damage. The aim of this review is to provide a deep understanding of these mechanisms and the pathogenesis of AIS. Later, we will discuss the potential therapies that have already demonstrated, in preclinical or clinical studies, to improve the outcomes of patients with AIS.

1 December 2019 in Pharmacological Reports
Verified
Journal Article
Closed access
BQBegoña Quintana-Villamandos
Begoña Quintana-Villamandos
MDMaría Jesús Delgado-Martos
María Jesús Delgado-Martos
EDEmilio Delgado-Baeza
Emilio Delgado-Baeza

25 September 2025 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
AAA. Arnalich-Montiel
A. Arnalich-Montiel
IBI. M. Barrio-Pérez
I. M. Barrio-Pérez
ABA. Burgos-Santamaría
A. Burgos-Santamaría
CFC. Fernández-Riveira
C. Fernández-Riveira
ALA. Lázaro
A. Lázaro
BQBegoña Quintana-Villamandos
Begoña Quintana-Villamandos
Acute kidney injury (AKI) frequently occurs after endovascular aortic aneurysm repair (EVAR), leading to significant morbidity and mortality. It is associated with contrast administration, hypovolemia, arterial microembolization due to renal artery manipulation, ischemia–reperfusion syndrome, and other patient comorbidities. However, little is known about the effect of volatile anesthetics on the development of AKI in this context. Therefore, we aimed to investigate renal function in patients anesthetized with desflurane or sevoflurane for EVAR. For this, we conducted a single-center randomized clinical trial involving 80 patients scheduled for elective EVAR under general anesthesia. Patients were randomly assigned to the desflurane or sevoflurane anesthesia group. Biochemical variables of kidney function and biomarkers for AKI were studied at three different time points: before surgery, after surgery, and 24 h after surgery. Plasma creatinine, cystatin C, estimated glomerular filtration, uric acid, and kidney injury molecule-1 did not significantly change between both groups. A mixed linear model demonstrated a significant interaction (p = 0.01) of plasma neutrophil gelatinase-associated lipocalin (NGAL) between sevoflurane and desflurane. Both groups showed a progressive increase in plasma NGAL (sevoflurane 3.713 ng/mL, p < 0.001 and desflurane 1.774 ng/mL, p < 0.001) when comparing the moment before surgery with respect to 24 h after surgery. However, sevoflurane caused a higher plasma NGAL concentration than desflurane after 24 h of surgery (8.66 ± 5.09 ng/mL vs. 6.51 ± 3.86 ng/mL, P = 0.03). Desflurane was associated with a lower postoperative AKI than sevoflurane in patients undergoing EVAR. Further research is required to corroborate our results and evaluate the clinical importance. Trial registration: EudraCT: 2016-003906-16; ClinicalTrials.gov: NCT03917186.

Verified
Journal Article
Open access
PDF file
ABAlba Burgos
Alba Burgos
PRPilar Rodríguez-Rodríguez
Pilar Rodríguez-Rodríguez
AAAna Arnalich-Montiel
Ana Arnalich-Montiel
Silvia ArribasSilvia Arribas
Silvia Arribas
CFCarmen Fernández-Riveira
Carmen Fernández-Riveira
BQBegoña Quintana-Villamandos
Begoña Quintana-Villamandos
An aortic aneurysm (AA) is a life-threatening condition. Oxidative stress may be a common pathway linking multiple mechanisms of an AA, including vascular inflammation and metalloproteinase activity. Endovascular aneurysm repair (EVAR) is the preferred surgical approach for AA treatment. During surgery, inflammation and ischemia–reperfusion injury occur, and reactive oxygen species (ROS) play a key role in their modulation. Increased perioperative oxidative stress is associated with higher postoperative complications. The use of volatile anesthetics during surgery has been shown to reduce oxidative stress. Individual biomarkers only partially reflect the oxidative status of the patients. A global indicator of oxidative stress (OXY-SCORE) has been validated in various pathologies. This study aimed to compare the effects of the main volatile anesthetics, sevoflurane and desflurane, on oxidative status during EVAR. Eighty consecutive patients undergoing EVAR were randomized into two groups: sevoflurane and desflurane. Plasma biomarkers of oxidative damage (protein carbonylation and malondialdehyde) and antioxidant defense (total thiols, glutathione, nitrates, superoxide dismutase, and catalase activity) were measured before surgery and 24 h after EVAR. The analysis of individual biomarkers showed no significant differences between the groups. However, the OXY-SCORE was positive in the desflurane group (indicating a shift towards antioxidants) and negative in the sevoflurane group (favoring oxidants) (p < 0.044). Compared to sevoflurane, desflurane had a positive effect on oxidative stress during EVAR. The OXY-SCORE could provide a more comprehensive perspective on oxidative stress in this patient population.

17 October 2022 in Antioxidants
Verified
Journal Article
Open access
PDF file
RMRaquel Martín-Oropesa
Raquel Martín-Oropesa
PRPilar Rodríguez-Rodríguez
Pilar Rodríguez-Rodríguez
LPLaia Pazó-Sayós
Laia Pazó-Sayós
AAAna Arnalich-Montiel
Ana Arnalich-Montiel
Silvia ArribasSilvia Arribas
Silvia Arribas
BQBegoña Quintana-Villamandos
Begoña Quintana-Villamandos
We previously observed that esmolol treatment for 48 h reduced vascular lesions in spontaneously hypertensive rats (SHRs). Therefore, we investigated whether this beneficial effect is persistent after withdrawal. Fourteen-month-old SHRs (SHR-Es) were treated with esmolol (300 μg/kg/min) or a vehicle for 48 h. Two separate groups were also given identical treatment, but they were then monitored for a further 1 week and 1 month after drug withdrawal. We analyzed the geometry and composition of the coronary artery, vascular reactivity and plasma redox status. Esmolol significantly decreased wall thickness (medial layer thickness and cell count), external diameter and cross-sectional area of the artery, and this effect persisted 1 month after drug withdrawal. Esmolol significantly improved endothelium-dependent relaxation by ACh (10−9–10−4 mol/L); this effect persisted 1 week (10−9–10−4 mol/L) and 1 month (10−6–10−4 mol/L) after withdrawal. Esmolol reduced the contraction induced by 5-HT (3 × 10−8–3 × 10−5 mol/L), and this effect persisted 1 week after withdrawal (10−6–3 × 10−5 mol/L). Esmolol increased nitrates and reduced glutathione, and it decreased malondialdehyde and carbonyls; this enhancement was maintained 1 month after withdrawal. This study shows that the effect of esmolol on coronary remodeling is persistent after treatment withdrawal in SHRs, and the improvement in plasma oxidative status can be implicated in this effect.

28 September 2026 in Anesthesiology
Verified
Journal Article
Closed access
JRJavier Ripollés-Melchor
Javier Ripollés-Melchor
ÁEÁngel V. Espinosa
Ángel V. Espinosa
MGManuel Ignacio Monge García
Manuel Ignacio Monge García
CACesar Aldecoa
Cesar Aldecoa
Manu MalbrainManu Malbrain
Manu Malbrain
AAAlfredo Abad-Gurumeta
Alfredo Abad-Gurumeta
Background: Whether protocolized intraoperative arterial pressure-targeting strategies provide incremental benefit beyond contemporary usual care remains uncertain. We performed a Bayesian meta-analysis of randomized trials in major noncardiac surgery. Methods: MEDLINE, Embase, and Cochrane CENTRAL were searched from inception to January 5, 2026, with additional literature surveillance through June 29, 2026. Randomized trials comparing protocolized intraoperative arterial pressure-targeting strategies with usual care or lower-pressure approaches were included. The primary outcome was all-cause mortality; secondary outcomes were acute kidney injury (AKI) and myocardial injury after noncardiac surgery (MINS). Bayesian random-effects meta-analysis was prespecified as the primary analytical framework, with confirmatory frequentist analyses. Results: Fifteen randomized trials met the inclusion criteria. Mortality (13 trials) remained centered around an OR of 1.00 (frequentist OR 1.00, 95% CI 0.83–1.21; Bayesian median OR 1.00, 95% CrI 0.73–1.38), with wide Bayesian prediction intervals (OR 0.56–1.78). AKI (14 trials) showed the most favorable estimates (frequentist OR 0.87, 95% CI 0.73–1.03; Bayesian median OR 0.88, 95% CrI 0.70–1.05), but estimates remained compatible with no clinically important benefit, heterogeneity was moderate, and leave-one-out analyses, excluding each trial in turn, showed sensitivity to individual-trial exclusion. MINS (8 trials) likewise remained compatible with no treatment effect (frequentist OR 1.04, 95% CI 0.93–1.15; Bayesian median OR 1.05, 95% CrI 0.90–1.26). Exploratory analyses suggested that any potential renal benefit may depend on the broader hemodynamic context in which arterial pressure targets are implemented. Conclusions: Protocolized intraoperative arterial pressure-targeting strategies did not demonstrate a consistent incremental benefit over contemporary usual care in major noncardiac surgery. Mortality and MINS remained compatible with no treatment effect. Although AKI showed the most favorable estimates, the evidence remained uncertain, was sensitive to individual-trial exclusion, and should be interpreted cautiously.